- A broad and maturing pipeline with candidates for a range of conditions
- Candidates at varying stages of development
- Healthy mix of partnered and non-partnered programmes
For a company our size, Vernalis has an impressive portfolio of drug candidates in pre-clinical and clinical development. Our extensive clinical expertise, and highly focused business direction should ensure optimal use of resources and balance the risks in our pipeline.
Vernalis collaboration with Tris
Latest status of the programmes for the US prescription cough cold market.
See at a glance what Vernalis has in development
Latest status of all priority programmes both partnered and un-partnered, plus legacy programmes.
Vernalis In-house Research
Our NCE pipeline has historically been fed by our in-house research team
We have partnered and independent programmes in this critical area
See the different candidates currently in development
Strong capabilities and extensive experience characterise this area
Three partnered programmes and one that we’re developing ourselves
Programmes beyond oncology and the central nervous system
Promising anti-inflammatory programmes
Tuesday, 09 April 2013
Vernalis plc (LSE: VER) today announces its audited results for the year ended 31 December 2012